EYENOVIA INC. news, videos and press releases
For more news please use our advanced search feature.
EYENOVIA INC. - More news...
EYENOVIA INC. - More news...
- Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
- Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
- Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
- Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
- Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
- Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
- Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
- Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
- Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
- Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
- Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
- Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
- Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
- Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
- Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
- Eyenovia Announces $12 Million Registered Direct Offering
- Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
- Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
- Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
- Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
- Eyenovia Announces First Commercial Sale of Mydcombi™
- Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
- Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
- Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
- Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
- Eyenovia Announces Poster Presentation at ARVO 2023
- Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
- Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
